Browse the evidence

GLP-1 receptor agonists (GLP-1 RAs) have shown promising potential in promoting weight loss and preventing diseases associated with obesity.

GLP-1 RAs may be considered as a pharmacologic option for obesity treatment.

Semaglutide and liraglutide have been approved as weight loss medications due to their effectiveness in promoting significant and sustained weight loss.

Clinicians can prescribe semaglutide and liraglutide for weight management in eligible patients.

GLP-1 agonists resulted in a percentage of change in body weight of -6.2% at six months.

GLP-1 agonists may be an effective option for weight loss in obese IBD patients.

58.3% of patients achieved a weight reduction of 5% or more at six months.

A significant portion of obese IBD patients may benefit from GLP-1 agonist therapy for weight loss.

Incretin-based therapies resulted in significant reductions in body weight and/or body mass index in patients with obstructive sleep apnea.

Practitioners may consider incretin-based therapies as effective options for weight management in OSA patients.

Tirzepatide has demonstrated significant body weight reductions in individuals with obesity but not diabetes.

Tirzepatide may be beneficial for weight management in patients with obesity.

Semaglutide is safe and effective for weight loss in obese, non-diabetic patients with end-stage kidney disease on haemodialysis.

Practitioners may consider semaglutide as a treatment option for weight loss in similar patient populations.

Semaglutide, a GLP-1 receptor agonist, demonstrated much greater weight loss than previous medications.

Practitioners may consider semaglutide as a more effective option for weight loss in obese patients.

GLP-1RA use in patients with metabolically unhealthy obesity (MUHO) is associated with a significantly lower risk of mortality (HR 0.580) compared to non-use.

Clinicians may consider GLP-1RAs for reducing mortality risk in MUHO patients.

Anti-obesity medications, particularly glucagon-like peptide-1 receptor agonists, have shown safety and weight loss efficacy in patients with heart failure with preserved ejection fraction.

Clinicians may consider glucagon-like peptide-1 receptor agonists for weight management in patients with heart failure with preserved ejection fraction.

Carbohydrate intake measures showed strong associations with weight loss at 3-, 6-, and 12-month time points.

Focusing on carbohydrate intake may enhance weight loss efforts.

Weight loss in both diet groups seems to have been driven by the reduction of glycemic load (GL) more so than dietary fat or calories.

Reducing glycemic load may be more effective for weight loss than focusing solely on fat or calorie reduction.

Tirzepatide has demonstrated superior weight loss efficacy compared to previously approved medications.

Tirzepatide may be considered as a more effective pharmacotherapy option for weight loss in patients compared to existing medications.

Orforglipron has advanced through Phase 3 clinical development, demonstrating significant reductions in hemoglobin A1c and body weight (up to 7.9%) with favorable tolerability.

Practitioners can consider Orforglipron as an effective option for managing hemoglobin A1c and body weight.

Novel incretin-based therapies have gained popularity due to their effectiveness in achieving substantial weight loss.

Healthcare providers should consider incretin-based therapies as effective options for weight management.

GLP-1 receptor agonists (GLP-1RAs) and dual GLP-1 and glucose-dependent insulinotropic polypeptide receptor agonists (GLP-1/GIPRA) significantly reduce body weight and adiposity.

Practitioners can expect significant weight loss and reduction in adiposity with GLP-1RA and GLP-1/GIPRA therapies.

Correcting hormonal deficiencies may improve exercise capacity and reduce major cardiac events.

Clinicians should consider hormonal assessments in patients at risk of cardiovascular events.

Patients in the clinical pharmacist cohort achieved a mean body weight reduction of 9.32% compared to 5.11% body weight reduction for patients in the primary care physician cohort.

Incorporating clinical pharmacists in weight management can lead to greater weight loss outcomes.

The use of long‐acting incretin‐based therapies, such as semaglutide, has increased due to their benefits for glycemic control in diabetes, cardiovascular risk reduction, and weight management.

Clinicians should consider the benefits of semaglutide for patients with diabetes and weight management needs.

Retatrutide exhibited significant reductions in glycated hemoglobin (HbA1c) and dose-dependent weight loss in individuals with type 2 diabetes mellitus (T2DM).

Retatrutide may be an effective treatment option for managing HbA1c and weight in T2DM patients.

In non-T2DM individuals, retatrutide produced substantial weight loss and improved glucose levels.

Retatrutide may also benefit non-T2DM individuals seeking weight loss and improved glucose control.

Behavioral interventions and pharmacological therapies may be effective strategies for weight management in PWH.

Integrating behavioral and pharmacological approaches may enhance weight management efforts in PWH.

New glucose-lowering drugs, such as sodium–glucose cotransporter 2 inhibitors and glucagon-like peptide-1 receptor agonists, have been confirmed to reduce weight and preserve kidney function.

Clinicians may consider these new drugs as effective treatment options for managing ORG.

Addition of glucagon receptor agonism enhances weight loss, reduces liver fat, and ameliorates dyslipidemia.

Practitioners should consider glucagon receptor agonists for their potential benefits in weight loss and metabolic health.